SAN ANTONIO--(BUSINESS WIRE)--KCI, an Acelity Company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s De Novo request for the PREVENA™ Incision Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback